This website collects cookies to deliver better user experience. Cookie Policy
Accept
Sign In
The Wall Street Publication
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Reading: FDA Rejects Short Sellers’ Request to Halt Trials of Alzheimer’s Drug
Share
The Wall Street PublicationThe Wall Street Publication
Font ResizerAa
Search
  • Home
  • Trending
  • U.S
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
    • Markets
    • Personal Finance
  • Tech
  • Lifestyle
    • Lifestyle
    • Style
    • Arts
  • Health
  • Sports
  • Entertainment
Have an existing account? Sign In
Follow US
© 2024 The Wall Street Publication. All Rights Reserved.
The Wall Street Publication > Blog > Business > FDA Rejects Short Sellers’ Request to Halt Trials of Alzheimer’s Drug
Business

FDA Rejects Short Sellers’ Request to Halt Trials of Alzheimer’s Drug

Editorial Board Published February 11, 2022
Share
FDA Rejects Short Sellers’ Request to Halt Trials of Alzheimer’s Drug
SHARE

The Food and Drug Administration has denied a petition by short sellers to halt clinical trials of an experimental Alzheimer’s drug being developed by Cassava Sciences Inc.

The two short sellers alleged in filings with the FDA and the Securities and Exchange Commission that Cassava’s published research contained images of experiments that appear to have been manipulated using software such as Photoshop. Cassava denied the allegations, and said it was cooperating with government investigations.

The FDA said Thursday it couldn’t launch an investigation based on claims in the so-called citizen’s petition filed by the short sellers. The petition process only allows the FDA to review or overturn regulations or orders the agency has already issued, the agency said.

“This response does not represent a decision by the Agency to take or refrain from taking any action relating to the subject matter of your Petitions,” Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, wrote in the letter.

A citizen’s petition allows members of the public to ask the FDA to take a regulatory action.

“The news is very welcome but not surprising,” said Cassava Chief Executive Remi Barbier. “We said from the outset that the allegations are false. I think the message may be that the FDA’s citizen petition privilege is not to be trifled with by stock market participants.”

Alzheimer’s is a progressive neurodegenerative disease affecting an estimated six million people in the U.S.

Shares of Austin, Texas-based Cassava closed at $135.30 in July, rallying on the prospects for its Alzheimer’s drug. The stock closed Thursday at $53.05.

The Wall Street Journal reported on the questions about Cassava’s Alzheimer’s drug, called Simufilam, and research in November. The SEC is investigating the short sellers’ allegations and the accuracy of statements that Cassava made to public investors, the Journal reported.

The short sellers, David Bredt and Geoffrey Pitt, filed the FDA citizen petition in August.

Dr. Bredt is a biotech entrepreneur and former neuroscience research chief at Johnson & Johnson and Eli Lilly & Co., while Dr. Pitt is a cardiologist and professor at Weill Cornell Medicine. They bet against Cassava’s stock before the petition became public, believing the share price would fall once their research was disclosed.

Jordan Thomas, an attorney for Messrs. Bredt and Pitt, said the petition was denied on a technicality. “Cassava Sciences has acknowledged that it is under investigation on multiple fronts and we will continue to cooperate with those federal law enforcement and regulatory authorities,” he said.

The Journal of Neuroscience, which published one of the papers on Simufilam and initially said it didn’t find evidence of data manipulation, last month published a statement of concern about the paper. The journal said it was aware of the allegations of image doctoring and is waiting on an outside investigation before taking further action.

Write to Joseph Walker at [email protected] and Dave Michaels at [email protected]

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Appeared in the February 11, 2022, print edition as ‘FDA Rebuffs Cassava Short Sellers.’

TAGGED:Business NewsPAIDWall Street Publication
Share This Article
Twitter Email Copy Link Print
Previous Article Biden dog Commander to make TV debut during ‘Puppy Bowl’ Biden dog Commander to make TV debut during ‘Puppy Bowl’
Next Article Elon Musk Expects Starship to Deliver Launches at Lower Costs Elon Musk Expects Starship to Deliver Launches at Lower Costs

Editor's Pick

California dwelling of lacking child’s mother and father searched; father has served time for youngster cruelty

California dwelling of lacking child’s mother and father searched; father has served time for youngster cruelty

San Bernardino County sheriff’s investigators on Sunday, Aug. 17, searched the house of the mother and father of the infant…

By Editorial Board 9 Min Read
Jenelle Evans OnlyFans Earnings Revealed, Within the MILLIONS
Jenelle Evans OnlyFans Earnings Revealed, Within the MILLIONS

Studying Time: 3 minutes Jenelle Evans has talked a giant recreation of…

5 Min Read
Determined seek for Northern California mother and child ends with tragic discovery
Determined seek for Northern California mother and child ends with tragic discovery

A determined search in Central California for a mom and her child…

4 Min Read

Oponion

Bomb hoax forces Chicago-bound flight to make emergency touchdown in distant Arctic metropolis

Bomb hoax forces Chicago-bound flight to make emergency touchdown in distant Arctic metropolis

An Air India flight en path to Chicago was compelled…

October 15, 2024

An replace on Blood Oxygen for Apple Watch within the U.S.

Apple will introduce a redesigned Blood…

August 14, 2025

Trump says the world respects us. Empty seats in Vegas show in any other case.

President Donald Trump is so disastrously…

August 17, 2025

Thanks, Trump! Criminals are actually impersonating ICE brokers

Police in Philadelphia are searching for…

June 10, 2025

Harris winds down marketing campaign with highly effective tribute to her mom’s legacy

Vice President Kamala Harris will get…

November 5, 2024

You Might Also Like

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution
Business

Thales Reinforces its Management in eSIM and IoT Connectivity with a ‘Ready to Use’ Licensed Resolution

At a time when billions of linked objects are reshaping industries, Thales has achieved a vital safety certification for its…

4 Min Read
Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality
Business

Soracom IoT Platform Achieves SOC 2 Kind 2 Compliance for Safety, Availability, and Confidentiality

Soracom, Inc., right now introduced that it has efficiently achieved System and Group Controls (SOC) 2 Kind 2 compliance, reinforcing…

2 Min Read
Mobile IoT Module Shipments Grew 23% in Q1 2025 as US–China tensions affect vendor panorama
Business

Mobile IoT Module Shipments Grew 23% in Q1 2025 as US–China tensions affect vendor panorama

In brief Shipments of mobile IoT modules and chipsets grew 23% year-over-year in Q1 2025, based on IoT Analytics’ International…

20 Min Read
Prime 7 Visitor Posting Marketplaces to Purchase Visitor Posts That Drive Search engine optimization Outcomes
Business

Prime 7 Visitor Posting Marketplaces to Purchase Visitor Posts That Drive Search engine optimization Outcomes

Utilizing a visitor posting market helps you overlook all that like a nasty nightmare. However how do you discover probably…

14 Min Read
The Wall Street Publication

About Us

The Wall Street Publication, a distinguished part of the Enspirers News Group, stands as a beacon of excellence in journalism. Committed to delivering unfiltered global news, we pride ourselves on our trusted coverage of Politics, Business, Technology, and more.

Company

  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • WP Creative Group
  • Accessibility Statement

Contact

  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability

Term of Use

  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices

© 2024 The Wall Street Publication. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?